{"url_path":"/sec/mirm/8-k/2026-05-18/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-18","source_url":"https://www.sec.gov/Archives/edgar/data/1759425/0001193125-26-228902-index.html","accession_number":"0001193125-26-228902","cik":"0001759425","ticker":"MIRM","issuer_name":"Mirum Pharmaceuticals, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1759425/0001193125-26-228902-index.html","primary_entity_key":"0001759425","primary_entity_name":"Mirum Pharmaceuticals, Inc."},"word_count":139,"has_tables":true,"body_markdown":"Item 9.01\n\nFinancial Statements and Exhibits.\n\n(d) Exhibits.\n\n \n\nExhibit\nNumber\n\n  \n\nDescription\n\n 4.1\n  \n[Indenture, dated as of May 15, 2026, between Mirum Pharmaceuticals, Inc. and U.S. Bank Trust Company, National Association, as trustee.](d113366dex41.htm)\n\n 4.2\n  \n[Form of Note, representing the Company’s 0.00% Convertible Senior Notes due 2032 (included as Exhibit A to the Indenture filed as Exhibit 4.1).](d113366dex41.htm)\n\n99.1\n  \n[Press Release issued by the Company on May 12, 2026.](d113366dex991.htm)\n\n99.2\n  \n[Press Release issued by the Company on May 12, 2026.](d113366dex992.htm)\n\n104\n  \nCover page interactive data file (embedded within the inline XBRL document).\n\nSIGNATURE\n\nPursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\n \n\n \nMirum Pharmaceuticals, Inc.\n\nDate: May 18, 2026\n \n\n \nBy:\n \n\n/s/ Christopher Peetz\n\n \n\n \n\n \nChristopher Peetz\n\n \n\n \n\n \nChief Executive Officer"}